IP Library › Granted Patent US 8,278,465
Granted Patent B2
US 8,278,465 · App. 12/960,134 · Granted Oct 2, 2012

Coumarin derivative having antitumor activity

Assignees: Chugai Seiyaku Kabushiki Kaisha; Sakai Toshiyuki
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,465
App. No.
12/960,134
Granted
Oct 2, 2012
Kind
B2
Abstract

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Claims (99)

1. A compound represented by general formula (11) below or a pharmaceutically acceptable salt thereof:

wherein:

G 1 , G 2 , and G 8 are each independently —CR 1 ═ or —C(-G 9 -X)═;

G 3 is —CR 1 ═;

one from among G 1 , G 2 , and G 8 is —C(-G 9 -X)═;

X is a C 1-6 alkyl group (where the C 1-6 alkyl group may optionally be substituted with a group selected from a halogen atom, a hydroxy group, a cyano group and —NR 56 R 57 ), an aryl group, a heterocyclic group, R 31 CS—, R 31 CO—, R 33 R 34 NCS—, R 33 R 34 NC═NH—, R 3 R 4 NCO— or R 33 R 34 NCO 2 —;

G 9 is a single bond, an oxygen atom, a sulfur atom, —(CR 35 R 36 ) 1 — (where 1 represents an integer of 1 to 3) or —NR 37 —;

Ring G 6 is a divalent 6-membered aryl group,

A is a group represented by general formula (2) below or a group represented by general formula (3) below:

G 4 is an oxygen atom;

G 5 is an oxygen atom;

G 7 is CH 2 ;

R 1 is a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group (where the C 1-6 alkyl group may optionally be substituted with a group selected from a halogen atom, a hydroxy group and —NR 46 R 47 ), a C 2-7 alkenyl group, a carbamoyl group or a C 2-7 alkynyl group (where the C 2-7 alkynyl group may optionally be substituted with a C 1-4 acyl group);

when G 2 or G 3 is —CR 1 ═, G 8 is —C(-G 9 -X)═, and X is R 3 R 4 NCO—, R 33 R 34 NC═NH— or R 33 R 34 NCS—; when G 1 or G 8 is —CR 1 ═, G 2 is —C(-G 9 -X)═, and X is R 3 R 4 NCO—, R 33 R 34 NC═NH— or R 33 R 34 NCS—; or when G 2 is —CR 1 ═, G 1 is —C(-G 9 -X)═, and X is R 3 R 4 NCO—, R 33 R 34 NC═NH— or R 33 R 34 NCS—, R 1 may form a single bond or —CH 2 — together with R 4 or R 34 ;

R 2 is a hydroxy group, a C 1-6 alkoxy group, —NR 48 R 49 or a C 1-6 alkyl group (where the C 1-6 alkyl group may optionally be substituted with a group selected from a halogen atom, a hydroxy group, a C 1-6 alkoxy group, a formyl group, —CO 2 R 50 and —CO 2 NR 51 R 52 );

R 3 , R 4 , R 6 , R 7 , R 9 , R 10 , R 31 , R 46 and R 47 are each independently a hydrogen atom, a C 1-6 alkoxy group, a C 3-8 cycloalkyl group or a C 1-6 alkyl group (where the C 1-6 alkyl group may optionally be substituted with a group selected from a cyano group, a halogen atom, a hydroxy group, a C 1-6 alkoxy group, —NR 13 R 14 , —CONR 28 R 29 and an aryl group);

R 33 and R 34 are each independently a hydrogen atom, a C 1-6 alkyl group or an aryl group;

the combination of R 3 and R 4 , combination of R 6 and R 7 , combination of R 9 and R 10 , combination of R 33 and R 34 , and combination of R 46 and R 47 may form, together with the nitrogen atom to which they are bonded, a 4- to 6-membered heterocyclic group having at least one nitrogen atom (where the heterocyclic group may optionally be fused with a benzene ring);

one R 35 group and one R 36 group are each independently a hydrogen atom, a halogen atom or a C 1-6 alkyl group;

R 13 , R 14 , R 56 and R 57 are each independently a hydrogen atom, a C 1-6 alkyl group, —COR 32 or —CO 2 R 32 ; and

R 5 , R 8 , R 28 , R 29 , R 32 , R 37 , R 38 , R 48 , R 49 , R 50 , R 51 , and R 52 are each independently a hydrogen atom or a C 1-6 alkyl group.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound represented by general formula (11) is a compound represented by general formula (1) below:

wherein:

X is a heteroaryl group or R 3 R 4 NCO—;

Y 1 and Y 2 are each independently —CR 11 ═;

Y 3 and Y 4 may be the same or different, and are each —CR 12 ═;

A is a group represented by general formula (2) below or a group represented by general formula (3) below:

R 1 is a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group, a C 2-7 alkenyl group, a carbamoyl group or a C 2-7 alkynyl group (where the C 2-7 alkynyl group may optionally be substituted with a C 1-4 acyl group);

R 2 is a C 1-6 alkyl group optionally substituted with a halogen atom;

R 3 , R 4 , R 6 , R 7 , R 9 and R 10 are each independently a hydrogen atom, a C 1-6 alkoxy group, a C 3-8 cycloalkyl group or a C 1-6 alkyl group (where the C 1-6 alkyl group may optionally be substituted with a group selected from a cyano group, a halogen atom, a hydroxy group, a C 1-6 alkoxy group and —NR 13 R 14 );

the combination of R 3 and R 4 , combination of R 6 and R 7 , and combination of R 9 and R 10 may form, together with the nitrogen atom to which they are bonded, a 4- to 6-membered heterocyclic group having at least one nitrogen atom;

R 5 , R 8 , R 13 and R 14 are each independently a hydrogen atom or a C 1-6 alkyl group;

R 11 is a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 1-4 acyl group, a C 1-4 acyloxy group or —NR 15 R 16 ;

R 12 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group; and

R 15 and R 16 are each independently a hydrogen atom or a C 1-4 acyl group.

3. The compound or pharmaceutically acceptable salt thereof according to claim 2 , wherein R 1 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group.

4. The compound or pharmaceutically acceptable salt thereof according to claim 2 , wherein R 5 or R 8 is a hydrogen atom.

5. The compound or pharmaceutically acceptable salt thereof according to claim 2 , wherein R 3 , R 4 , R 6 , R 7 , R 9 and R 10 are each independently a hydrogen atom or a C 1-6 alkyl group.

6. The compound or pharmaceutically acceptable salt thereof according to claim 2 , wherein X is a thiazol-2-yl group, a pyrimidin-2-yl group, a 2-pyridyl group or R 3 R 4 NCO— (where R 3 and R 4 have the same definitions as above).

7. The compound or pharmaceutically acceptable salt thereof according to claim 2 , which is selected from:

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-fluoro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-aminosulfonylamino-2-fluoro-benzyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{2-fluoro-3-(aminosulfonyl)aminobenzyl}-6-fluoro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-iodo-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-methyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-cyano-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-fluoro-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-{3-(aminosulfonyl)aminobenzyl}-6-chloro-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-aminosulfonylamino-2-fluoro-benzyl)-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

3-{2-fluoro-3-(aminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{3-(aminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{3-(aminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-6-chloro-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(aminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{3-(aminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-6-methyl-2-oxo-2H-1-benzopyran,

3-{2-chloro-3-(aminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

dimethylcarbamic acid 4-methyl-3-{3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 6-fluoro-4-methyl-3-{3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-(N-methylsulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-methylaminosulfonylamino-2-fluoro-benzyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 6-iodo-4-methyl-3-{3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 6-methyl-4-methyl-3-{3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 6-cyano-4-methyl-3-{3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-methylaminosulfonylamino-2-fluoro-benzyl)-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-methylaminosulfonylaminobenzyl)-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-methylaminosulfonylaminobenzyl)-6-fluoro-4-fluoromethyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 6-chloro-4-fluoromethyl-3-{3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-6-fluoro-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-fluoromethyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-6-chloro-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(thiazol-2-yloxy)-6-methyl-2-oxo-2H-1-benzopyran,

dimethylcarbamic acid 6-chloro-4-methyl-3-{3-(dimethylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester,

3-{2-fluoro-3-(dimethylaminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

dimethylcarbamic acid 3-(3-(N-(2-cyanoethyl)sulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-(N-(2-hydroxyethyl)sulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-(N-(2-methoxyethyl)sulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-(N-(2-aminoethyl)sulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester hydrochloride,

dimethylcarbamic acid 3-(3-(N—(N′-methyl-2-aminoethyl)methylsulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester hydrochloride,

dimethylcarbamic acid 3-(3-(N-2,2,2-trifluoroethyl-sulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-(N-methoxysulfamoyl)aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-carbamoylmethanesulfonylamino-benzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

dimethylcarbamic acid 3-(3-methylcarbamoylmethanesulfonylamino-benzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

2-{2-fluoro-3-[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2H-1-benzopyran-3-ylmethyl]phenylsulfamoyl}-N-methyl-acetamide,

dimethylcarbamic acid 3-(3-dimethylcarbamoylmethanesulfonylamino-benzyl)-6-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester,

2-{2-fluoro-3-[4-methyl-2-oxo-7-(thiazol-2-yloxy)-2H-1-benzopyran-3-ylmethyl]phenylsulfamoyl}-N-methyl-acetamide,

3-{2-methyl-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(5-fluoropyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(4-chloropyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(2,4-dimethoxypyrimidin-6-yloxy)-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(benzothiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(5-bromothiazol-2-yloxy)-2-oxo-2H-1-benzopyran,

dimethylcarbamic acid 6-fluoro-4-methyl-3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-2-oxo-2H-1-benzopyran-7-yl ester.

8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

9. The compound or pharmaceutically acceptable salt thereof according to claim 2 , which is 3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran.

Priority Claims (1)
JP P2006-032903 · Feb 9, 2006 · national
Continuity (2)
Division 12161256
Related Publication 20110092700A1 · Apr 21, 2011